復宏漢霖聯合創始人劉世高博士加入伊甸生醫董事會 | 美體產業公開資訊

2021年3月15日—劉博士於2010年聯合創辦上海復宏漢霖生物技術公司（股票代碼：2696.HK）並擔任總裁暨執行長，成功帶領該公司市值超過200億港元（現已 ...

Eden Biologics is honored to announce the addition of Dr. Scott Liu as a member of the Eden Board of Directors. Effective March 15, 2021, Dr. Liu will be added to a team of top global biotech executives and guide Eden in achieving its mission: To make world-class biopharmaceuticals affordable and available to more patients worldwide. Dr. Liu previously retired from Shanghai Henlius Biotech, Inc. (2696.HK) which he Co-Founded in 2010, held positions as President & CEO, and was integral in building the company to have a valuation of over 20 Billion HKD.

Under his leadership, Henlius built a strong pipeline of more than 10 biosimilars and 20 innovative biologics, including 3 biosimilars approved in China and 1 approved in the European Union. He led the first biosimilar product ever to be approved in China. He believes Eden Biologics already has a strong fundamental concentration on Quality and possesses the ...